BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development
Globenewswire·2025-04-28 11:30
Overall survival and clinical benefit in Phase 2 continue to outperform historical benchmarks, including very heavily pretreated patientsClinical benefit observed in 83% of evaluable patient sub-group treated with the phase 3 formulationImproved new Bria-OTS+ platform provides powerful innate and adaptive immune system activationPhase 3 biomarker data to be presented on Wed April 30 from 9:00 AM - 12:00 PM CST; Abstract # LB408 PHILADELPHIA and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- ...